4D Molecular Therapeutics’ (FDMT) Sell (D-) Rating Reiterated at Weiss Ratings

Weiss Ratings reiterated their sell (d-) rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT) in a research note published on Wednesday morning,Weiss Ratings reports.

FDMT has been the subject of several other reports. Bank of America decreased their price objective on shares of 4D Molecular Therapeutics from $79.00 to $46.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. Royal Bank of Canada decreased their price target on shares of 4D Molecular Therapeutics from $40.00 to $39.00 and set an “outperform” rating for the company in a report on Thursday, November 14th. BMO Capital Markets lowered 4D Molecular Therapeutics from an “outperform” rating to a “market perform” rating and dropped their price objective for the stock from $40.00 to $15.00 in a research note on Monday, January 13th. Chardan Capital cut their price objective on 4D Molecular Therapeutics from $39.00 to $30.00 and set a “buy” rating for the company in a research report on Tuesday, February 11th. Finally, Leerink Partners lowered their target price on 4D Molecular Therapeutics from $31.00 to $27.00 and set an “outperform” rating on the stock in a report on Monday, January 13th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, 4D Molecular Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $32.13.

4D Molecular Therapeutics Stock Down 0.6 %

Shares of FDMT opened at $4.64 on Wednesday. The firm has a market cap of $214.50 million, a price-to-earnings ratio of -1.63 and a beta of 2.81. The company’s fifty day moving average is $5.38 and its 200-day moving average is $9.00. 4D Molecular Therapeutics has a 12 month low of $4.41 and a 12 month high of $36.25.

Institutional Trading of 4D Molecular Therapeutics

A number of hedge funds have recently modified their holdings of FDMT. Decheng Capital LLC raised its stake in shares of 4D Molecular Therapeutics by 0.5% in the fourth quarter. Decheng Capital LLC now owns 400,000 shares of the company’s stock valued at $2,228,000 after purchasing an additional 2,165 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in 4D Molecular Therapeutics by 7.1% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 44,324 shares of the company’s stock valued at $247,000 after buying an additional 2,925 shares during the period. PNC Financial Services Group Inc. raised its stake in shares of 4D Molecular Therapeutics by 66.1% in the 4th quarter. PNC Financial Services Group Inc. now owns 9,124 shares of the company’s stock valued at $51,000 after buying an additional 3,630 shares in the last quarter. Rhumbline Advisers lifted its holdings in shares of 4D Molecular Therapeutics by 5.3% during the 4th quarter. Rhumbline Advisers now owns 73,431 shares of the company’s stock worth $409,000 after acquiring an additional 3,675 shares during the period. Finally, ProShare Advisors LLC boosted its position in shares of 4D Molecular Therapeutics by 30.1% during the 4th quarter. ProShare Advisors LLC now owns 16,369 shares of the company’s stock valued at $91,000 after acquiring an additional 3,783 shares in the last quarter. Institutional investors own 99.27% of the company’s stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.